Saint Luke’s Radiology Department pursues investigator-initiated research projects with the goal of improved patient outcomes. Research efforts have resulted in outside funding from the biotechnology industry as well as the Kansas Bioscience Authority.
Saint Luke’s Hospital of Kansas City is the only hospital in the Kansas City region that employs radiologists with expertise in dedicated interpretation of thoracic imaging. Radiologist subspecialists, recognized at national and international levels, are utilizing two to three decades of imaging expertise to lead the multidisciplinary team of lung cancer experts in the 2013-initiated Saint Luke’s Hospital of Kansas City Lung Cancer Screening Program. Patients screened in this program receive low-dose chest CT scans and the advantage of diagnostic and treatment expertise from a host of medical specialists at Saint Luke’s.
Jeff Kunin, M.D., continued his investigatorinitiated study, “The Role of EarlyCDT®-Lung in the Management of Pulmonary Nodules,” with co-investigators from Radiology, Pulmonary Medicine, and Cardiology. This innovative study is evaluating and correlating human autoantibodies targeting lung cancer with pulmonary nodules found on computed tomography (CT) scans with a simple blood test called EarlyCDT®-Lung. This blood test has the potential to distinguish benign from malignant pulmonary nodules. Patient enrollment has closed. Investigators are currently analyzing the data. The study is funded by Oncimmune Ltd., the Kansas Bioscience Authority, and Saint Luke’s Foundation.
Brandt C. Wible, M.D., is investigating IVC filter retrieval rates at Saint Luke’s Hospital. This prospective study evaluates potential patient scheduling alterations designed to improve retrieval rates of IVC filters in appropriate patients at Saint Luke’s Hospital.
Nathan Saucier, M.D., is leading a study titled “Comparison of Complication and Long-Term Patency Rates of Two Tunneled Dialysis Catheters: Angiodynamics BioFlo DuraMax® vs. Covidien Palindrome™ HIS.” The purpose of this study is to compare the rates of patency and infection between two different catheters: the primary tunneled hemodialysis catheter currently used at Saint Luke’s Hospital—the Palindrome HIS, a heparin- and silver ion-coated catheter—to the recently FDA-approved BioFlo DuraMax hemodialysis catheter, which uses fluorine oligomer technology.
For more information, call 816-932-2549.